Loading
Novavax Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Mar 2023.
Novavax Inc: what insiders have been doing
This page follows insider dealings at Novavax Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Gaithersburg, United States. The group dates from 1987. 10 insiders have disclosed 18 filings since 18 October 2025.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Insider buying of Novavax Inc has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 18 filings, this issuer sits below that mark. Looking back to 2016, when coverage begins, insiders filed 7 purchases and 11 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 1.12 bn USD and net income at 440.3 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
173
Thresholds
n/a
Buy Volume
€101,430
7 ops. · all time
Sell Volume
€2M
11 ops. · all time
Who traded when
BuySaleJames F. Young1 sale
Rachel K. King1 sale
Since the insiders bought
- -64.8%Entry US$145.92 · Close at T+365 US$51.40
- -72.3%Entry US$94.00 · Close at T+365 US$26.00
- -72.3%Entry US$94.00 · Close at T+365 US$26.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Novavax Inc Buy (bullish), based on 9 analysts. Average price target: US$14.11.
Fundamental score
Ranked 1,132 of 24,161 companies
79.1
score / 100
Value69
Quality90
FCF yld-14%
Earn yld24%
EV/EBITDA4.3x
ROE·
Gross mgn93%
Net mgn39%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$12.82
Analyst consensus
9 analystsBuy
US$7.00Target US$14.11(+10%)US$25.00
Income statement
RevenueUS$1.1B
Gross profitUS$1.1B93% margin
EBITDAUS$492.3M44% margin
Net incomeUS$440.3M-59.9% margin
Valuation
PER (forward)-78.2x
Beta2.44
Balance sheet & cash
Market capUS$2.1B
Total debtUS$248.8M
Free Cash Flow-US$251M
Profitability & ownership
ROA-6.5%
% insiders5.0%
% institutions67.5%
Last declaration on 23 June 2026
Declarations173 total
18,880 sharesCommon StockSEC:0001104659-26-076924:0
18,880 sharesCommon StockSEC:0001104659-26-076927:0
9,520 shares0Common StockSEC:0001104659-26-050457:0
7,947 shares0Common StockSEC:0001104659-26-027143:0
12,223 shares0Common StockSEC:0001104659-26-025369:0
56,334 shares0Common StockSEC:0001104659-26-023720:0
37,500 shares0Common StockSEC:0001104659-26-023715:0
43,167 shares0Common StockSEC:0001104659-26-023731:0
150,167 shares0Common StockSEC:0001104659-26-023726:0
26,667 shares0Common StockSEC:0001104659-26-023709:0
83,333 shares0Common StockSEC:0001104659-26-023074:0
58,666 shares0Common StockSEC:0001104659-26-023072:0
19,600 shares0Common StockSEC:0001104659-26-023070:0
4,000 shares0Common StockSEC:0001104659-26-023069:0
83,197 shares0Common StockSEC:0001104659-26-006721:0
41,899 shares0Common StockSEC:0001104659-25-121103:0
14,257 shares0Common StockSEC:0001104659-25-111494:0
3,800 sharesCommon StockSEC:0001104659-25-104413:0
10,420 shares0Common StockSEC:0001593968-25-000784:0
10,420 shares0Common StockSEC:0001593968-25-000783:0
10,420 shares0Common StockSEC:0001593968-25-000758:0
10,420 shares0Common StockSEC:0001593968-25-000760:0
10,420 shares0Common StockSEC:0001593968-25-000759:0
10,420 shares0Common StockSEC:0001593968-25-000757:0
12,223 shares0Common StockSEC:0001593968-25-000332:0
25 of 173 declarations
About Novavax Inc
Novavax, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq (NASDAQ: NVAX) and headquartered in Gaithersburg, Maryland, United States. For investors, the company stands out as a vaccine-focused biotech with a platform asset story rather than a broad commercial pharma model. Founded in 1987, Novavax has built its business around recombinant-protein vaccine design and its proprietary Matrix-M adjuvant technology, which is intended to enhance immune responses and can be licensed into multiple vaccine programs. ([novavax.com](https://www.novavax.com/about-us))
Novavax’s best-known product is Nuvaxovid, its recombinant protein-based COVID-19 vaccine. In May 2025, the company announced U.S. FDA approval of the BLA for its COVID-19 vaccine, and management emphasized that Nuvaxovid is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the United States. That approval also triggered a Sanofi milestone payment, underscoring how Novavax has increasingly converted clinical and regulatory progress into partnership economics. ([novavax.com](https://www.novavax.com/press-releases/2025-05-19-U-S-FDA-Approves-BLA-for-Novavaxs-COVID-19-Vaccine))
Read moreShow less
The company’s business model now has three main revenue engines: direct commercial sales of Nuvaxovid where it serves as commercial lead, supply sales of adjuvant and other components to partners, and licensing, royalties and milestone income from its technology platform. A major strategic shift came with the May 2024 Sanofi collaboration and license agreement, under which Novavax and Sanofi co-commercialize the COVID-19 vaccine and Sanofi can develop influenza-COVID combination vaccines and other products using Matrix-M. Novavax also continues to work with partners such as Takeda and Serum Institute of India, giving it a broader geographic footprint across the United States, Europe and selected international markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000015/novavax2024annualreport429.pdf))
From a competitive perspective, Novavax occupies a niche in the vaccine market. Its protein-based approach offers a differentiated profile versus mRNA platforms, but the company remains much smaller than global vaccine leaders and is still highly dependent on execution, regulatory momentum, and partner demand. The strategic value of Matrix-M is central: management has consistently framed the adjuvant as a standalone monetizable asset and as a tool to expand into additional infectious-disease programs and, potentially, oncology-adjacent applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000015/novavax2024annualreport429.pdf))
Recent developments have reinforced that repositioning. In January 2026, Novavax announced a license agreement with Pfizer for Matrix-M in two infectious disease areas, with upfront cash, potential milestones and royalties. In its first-quarter 2026 update, Novavax said Matrix-M contributed $30 million related to that Pfizer agreement. Combined with the Sanofi partnership and ongoing efforts to advance early-stage pipeline candidates, the company is increasingly presenting itself as a lean vaccine platform company rather than a single-product story. For investors following SEC Form 4 insider activity, the key analytical lens remains the durability of partnership revenue, the commercial trajectory of Nuvaxovid, and the ability to expand Matrix-M into repeatable licensing economics. ([ir.novavax.com](https://ir.novavax.com/press-releases/2026-02-26-Novavax-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Highlights?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
